Podcasts about Bayer

In our news wrap Friday, President Trump ramped up his threats about taking over Greenland and suggested that he may place tariffs on countries that don't support the move, the Supreme Court says it will hear an appeal from Bayer to block thousands of state lawsuits claiming its Roundup weedkiller causes cancer and the Trump administration says it will delay involuntary student loan collections. PBS News is supported by - https://www.pbs.org/newshour/about/funders. Hosted on Acast. See acast.com/privacy

Following a framework plan announced by Democrat legislators yesterday, Senate Republican leaders today discussed their own framework plan to bring additional assistance for farmers and specialty crop farmers. The Supreme Court today agreed to hear Bayer's challenge to Roundup litigation. 

In our news wrap Friday, President Trump ramped up his threats about taking over Greenland and suggested that he may place tariffs on countries that don't support the move, the Supreme Court says it will hear an appeal from Bayer to block thousands of state lawsuits claiming its Roundup weedkiller causes cancer and the Trump administration says it will delay involuntary student loan collections. PBS News is supported by - https://www.pbs.org/newshour/about/funders. Hosted on Acast. See acast.com/privacy

In this enlightening episode, Guy interviewed Cyndi to explore overarching themes of holistic health, empowerment, community, and personal journey through adversity and spiritual growth. The conversation delved into how modern influences are detrimentally impacting mental, physical, and spiritual well-being, and emphasizes the importance of self-education and community support. Cyndi shared her inspiring family background, the legacy of her parents, and transformative experiences that shaped her pursuit of health and wellness. The discussion also touched on her focus on local, sustainable farming practices and the impact of legislative decisions on personal and community health. Cyndi provided actionable insights on the significance of choosing real food, supporting local businesses, and fostering innate intelligence for a more empowered and healthier life. About Cyndi: Cyndi O'Meara is a nutritionist and educator whose greatest love is to teach, both in the public arena and within the large corporate food companies, and to enable everyone to make better choices so they too can enjoy greater health throughout their lives.  Her unique, surprisingly simple yet extensively researched but down-to-earth approach, challenges and encourages others to eliminate unhealthy habits and has inspired thousands to make smarter choices about the food they choose to put into their body. Cyndi confronts her audiences, whether within the public or corporate sectors, she has the courage to call out deception and misinformation and believes in arming people with the tools and resources to reach their goals. By educating people on food choices, how to read food labels, why diets don't work, and how drugs can affect your total well-being and vitality, Cyndi empowers them to make long lasting changes with simple and achievable steps on how to create healthier habits. Key Points Discussed:  (00:00) - The Great Disconnect — How We Lost Touch With Our Body, Health, & Inner Knowing! (00:33) - Meet Cyndi: A Go-Getter's Background (01:31) - Family Influence and Upbringing (02:41) - Health Journey and Philosophy (08:22) - Educational Path and Realizations (08:56) - Adventures and Further Education (13:18) - Current Practices and Beliefs (16:53) - Community and Local Support (23:37) - Facing Adversity and Family Challenges (25:28) - Family History of Hemophilia (26:32) - The Impact of Bayer's Negligence (28:06) - Personal Losses and Reflections (30:49) - Spiritual Awakening and Healing (31:58) - Advocacy and Education (41:56) - Future Plans and Legacy (46:54) - Final Thoughts and Empowerment How to Contact Cyndi O'Meara:changinghabits.com.au whatswithwheat.com   About me:My Instagram: www.instagram.com/guyhlawrence/?hl=en Guy's websites:www.guylawrence.com.au www.liveinflow.co''

In der heutigen Folge sprechen die Finanzjournalisten Daniel Eckert und Lea Oetjen über bittere Enttäuschungen bei den US-Großbanken, die fünf Blockbuster von Bayer und den großen Oracle-Streit. Außerdem geht es um Bank of America, Citigroup, Wells Fargo, Tesla, Fresenius Medical Care, RWE, KKR & Co, Apollo Global Management, EQT AB, iShares MSCI Japan (WKN: A0DK60), Vanguard FTSE Japan Distributing (WKN: A1T8FU) und Amundi Core MSCI Japan (WKN: LYX0YC). Wir freuen uns an Feedback über aaa@welt.de. Noch mehr "Alles auf Aktien" findet Ihr bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts und AAA-Newsletter. Hier bei WELT: https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html. Der Börsen-Podcast Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? Hier findest du alle Infos & Rabatte! https://linktr.ee/alles_auf_aktien Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

Gabrielle Union stops by to chat about her upcoming projects, family, travel, and her partnership with Bayer for the ‘Life Doesn't Stop for a Hot Flash' campaign. Also, Sarah Jessica Parker drops in to discuss winning the Golden Globe ‘Carol Burnett Award,' her new documentary ‘The Librarians,' and what it's like saying goodbye to ‘And Just Like That…' Plus, TODAY lifestyle and fashion contributor Melissa Garcia and celebrity hairstylist Rita Hazan team up to give a few lucky mom listeners a makeover. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Dr. Hope Rugo and Dr. Vivek Subbiah discuss innovative trial designs to enable robust studies for smaller patient populations, as well as the promise of precision medicine, novel therapeutic approaches, and global partnerships to advance rare cancer research and improve patient outcomes. TRANSCRIPT  Dr. Hope Rugo: Hello and welcome to By the Book, a podcast series from ASCO that features engaging conversations between editors and authors of the ASCO Educational Book. I am your host, Dr. Hope Rugo. I am the director of the Women's Cancers Program and division chief of breast medical oncology at the City of Hope Cancer Center [in Los Angeles]. The field of rare cancer research is rapidly transforming thanks to progress in clinical trials and treatment strategies, as well as improvements in precision medicine and next-generation sequencing that enable biomarker identification. According to the National Cancer Institute, rare cancers occur in fewer than 150 cases per million each year, but collectively, they represent a significant portion of all cancer diagnoses. And we struggle with the appropriate treatment for these rare cancers in clinical practice. Today, I am delighted to be joined by Dr. Vivek Subbiah, a medical oncologist and the chief of early-phase drug development at the Sarah Cannon Research Institute in Nashville, Tennessee. Dr. Subbiah is the lead author of a paper in the ASCO Educational Book titled "Designing Clinical Trials for Patients with Rare Cancers: Connecting the Zebras," a great title for this topic. He will be telling us about innovative trial designs to enable robust studies for small patient populations, the promise of precision medicine, and novel therapeutic approaches to improve outcomes, and how we can leverage AI now to enroll more patients with rare cancers in clinical trials. Our full disclosures are available in the transcript of this episode.  Dr. Subbiah, it is great to have you on the podcast today. Thanks so much for being here. Dr. Vivek Subbiah: Thank you so much, Dr. Rugo, and it is an honor and pleasure being here. And thank you for doing this podcast for rare cancers. Dr. Hope Rugo: Absolutely. We are excited to talk to you. And congratulations on this fantastic paper. It is such a great resource for our community to better understand what is new in the field of rare cancer research. Of course, rare cancers are complex and multifaceted diseases. And this is a huge challenge for clinical oncologists. You know, our clinics, of course, cannot be designed as we are being very uni-cancer focused to just be for one cancer that is very rare. So, oncologists have to be a jack of all trades in this area. Your paper notes that there are approximately 200 distinct types of rare and ultra-rare cancers. And, by definition, all pediatric cancers are rare cancers. Of course, clinical trials are essential for developing new treatment strategies and improving patient outcomes, and in your paper, you highlight some unique challenges in conducting trials in this rare cancer space. Can you tell us about the challenges and how really innovative trial designs, I think a key issue, are being tailored to the specific needs of patients with rare cancer and, importantly, for these trials? Dr. Vivek Subbiah: Rare cancers present a perfect storm of challenges. First, the patient populations are very small, which makes it really hard to recruit enough participants for traditional type trials. Second, these patients are often geographically dispersed across multiple cities, across multiple states, across multiple countries, across multiple zip codes. So, logistics become complicated. Third, there is often limited awareness among clinicians, which delays referrals and diagnosis. Add to that regulatory hurdles, funding constraints, and you can see why rare cancer trials are so tough to execute. To overcome these barriers, we are seeing some really creative novel trial designs. And there are four different types of trial designs that are helping with enrolling patients with rare cancers. The first one is the basket trial. So let us talk about what basket studies are. Basket studies group patients based on shared genetic biomarkers or shared genetic mutations rather than tumor type. So instead of running separate 20 to 30 to 40 trials, you can study one therapy across multiple cancers. The second type of trial is the umbrella trial. The umbrella trials flip that concept of basket studies. They focus on one cancer type but test multiple targeted therapies within it. The third category of innovative trials are the platform studies. Platform trials are another exciting innovation. They allow new treatment arms to be added or removed as the data matures and as the data evolves, making trials more adaptive and efficient. The final category are decentralized tools in traditional trials, which are helping patients participate closer to where they are so that they can sleep in their own bed, which is, I think, a game changer for accessibility.  These designs maximize efficiency and feasibility for rare cancer research and rare cancer clinical trials. Dr. Hope Rugo: I love the idea of the platform trials that are decentralized. And I know that there is a trial being worked on with ARPA-H (Advanced Research Projects Agency for Health) funding in triple-negative breast cancer as well as in lung cancer, I think, and others with this idea of a platform trial. But it is challenged, I think, by precision medicine and next-generation sequencing where some patients do not have targetable markers, or there isn't a drug to target the marker. I think those are almost the same thing. We have really seen that these precision medicine ideas and NGS have moved the needle in helping to identify genetic alterations. This helps us to be more personalized. It actually helps with platform studies to customize trial enrollment. And we hope that this will result in better outcomes. It also allows us, I think, to study drugs even in the early stage setting more effectively. How can these advances be best applied to the future of rare cancers, as well as the challenges of not finding a marker or not having a drug? Dr. Vivek Subbiah: Thank you so much for that question. I think precision medicine and next-gen sequencing, or NGS, are truly the backbone of modern precision oncology. They have transformed how we think about cancer treatment. Instead of treating based on where the tumor originated or where the tumor started, we now look at the genetic blueprint of cancer. The NGS or next-gen sequencing allows us to sequence millions of DNA fragments quickly. Twenty, 30 years ago, they said we cannot sequence a human genome. Then it took almost a decade to sequence the first human genome. Right now, we have academic centers and commercial sequencing companies that are really democratizing NGS across all sites, not just in academic centers, across all the community sites, so that NGS is now accessible. This means that we can identify these actionable alterations like picking needles in haystacks, like NTRK fusions, RET fusions, or BRAF V600E alterations, high tumor mutational burden. This might occur across not one tumor type, across several different tumor types. So for rare cancers, this is critical because some of these mutations often define the best treatment option. Here is why this matters. Personalized therapy, right? Instead of a one-size-fits-all approach, we can tailor treatment to the patient's unique molecular profile. For trial enrollment, this can definitely help because patients can join biomarker-driven trials even if their cancer type is rare or ultra-rare. NGS technology has also helped us in designing rational studies. Many times monotherapy does not work in these cancers. So we are thinking about rational combination strategies. So NGS technology is helping us. Looking ahead, I see NGS becoming routine in clinical practice, not just at major niche academic centers, but everywhere. We will see more tumor-agnostic approvals, more molecular tumor boards guiding treatment decisions in real time. And I think we are seeing an expanded biomarker setup. Previously, we used to have only a few drugs and a handful of mutations. Now with homologous recombination defects, BRCA1/2 mutation, and expanding the HRD and also immunohistochemistry, we are expanding the biomarker portfolio. So again, I personally believe that the future is precision. What I mean by precision is delivering the right drug to the right patient at the right time. And for rare cancers, this isn't just progress. It is survival. And it is maybe the only way that they can have access to these cutting-edge precision medicines. Dr. Hope Rugo: That is so important. You mentioned an important area we will get to in a moment, the tumor-agnostic therapies. But as part of talking about that, do you think that the trials should also include just standard therapies? You know, who do you give an ADC to and when with these rare cancers? Because some of them do not have biomarkers to target and it is so disappointing for patients and providers where you are trying to screen a patient for a trial or a platform trial where you have one arm with this mutation, one arm with that, and they do not qualify because they only have a p53 loss, you know? They just do not have the marker that helps them. But we see this in breast cancer all the time. And it is tough because we don't have good information on the sequencing. So I wonder, you know, just because for some of these rare cancers it is not even clear what to use when with standard treatments. And then that kind of gets into this idea of the tumor-agnostic therapies that you mentioned. There are a lot of new treatments that are being evaluated. We have seen approval of some treatments in the last few years that are tumor-agnostic and based on a biomarker. Is that the best approach as we go forward for rare cancers? And what new treatment options are most exciting to you right now? Dr. Vivek Subbiah: Tumor-agnostic therapies, really close to my heart, are real breakthrough therapies and represent a major paradigm shift in oncology. Traditionally, for the broad listeners here, we are used to thinking about designing clinical trials and therapy like where the cancer originated, breast cancer, kidney cancer, prostate cancer, lung cancer. A tumor-agnostic therapy flips that model. Instead of focusing on the organ, they target the specific genetic alteration or biomarker that drives cancer growth regardless of where the tumor started, regardless of the location of the tumor, regardless of the zip code of the tumor. So why is this so important for rare cancers? Because many rare cancers share molecular features with more common cancers. For instance, NTRK fusion might occur in pediatric sarcoma, a salivary gland tumor, or a thyroid cancer. Historically, each of these would require separate trials, which is nearly impossible, unfeasible to conduct in these ultra-rare cancers like salivary gland cancer or pediatric sarcomas. Tumor-agnostic therapies allow us to treat all those cancers with the same targeted drug if they share that biomarker. Again, we are in 2025. The first tissue-agnostic approval, the historic precedent, was in fact an immunotherapy. Pembrolizumab was approved in 2017, May 2017, as the first immunotherapy to be approved in a tumor-agnostic way for a genomic biomarker, for MSI-High and dMMR cancers. Then came the NTRK inhibitors. So today we have not one, not two, but three different NTRK inhibitors: larotrectinib, entrectinib, and repotrectinib, which show response rates of nearly more than 60 to 75% across a handful of dozens and dozens of cancer types. Then, of course, we have RET inhibitors like selpercatinib, which is approved tissue-agnostic, and pralsetinib, which also shows tissue-agnostic activity across multiple cancers. And more recently, combination therapy with a BRAF and MEK combination, dabrafenib and trametinib, received tumor-agnostic approval for all BRAF V600E tumors with the exception of colorectal cancer. And even recently, you mentioned about antibody drug conjugates. Again, I think we live in an era of antibody drug conjugates. And Enhertu, trastuzumab deruxtecan, which was used first in breast cancer, now it is approved in a histology-agnostic manner for all HER2-positive tumors defined by immunohistochemistry 3+. So again, beyond NGS, now immunohistochemistry for HER2 is also becoming a biomarker. So again, for the broad listeners here, in addition to comprehensive NGS that may allow patients to find treatment options for these rare cancers for NTRK, RET, and BRAF, immunohistochemistry for HER2 positivity is also emerging as a biomarker given that we have a new FDA approval for this. So I would say personally that these therapies are game changers because they open doors for patients who previously had no options. Instead of waiting for years for a trial in their specific cancer type, they can access a treatment based on their molecular profile. I think it is precision medicine at its finest and best. Looking ahead, the third question you asked me is what is exciting going on? I think we will see more of these approvals. My hope is that today, I think we have nine to ten approvals. My hope is that within the next 25 to 50 years, we will have at least 50 to 100 drugs approved in this space based on a biomarker, not based on a location of the tumor type. Drug targeting rare alterations like FGFR2 fusions, FGFR amplifications, ALK fusions, and even complex signatures like high tumor mutational burden. I think we will be seeing hopefully more and more drugs approved. And as sequencing becomes routine, we will identify more patients for these therapies. I think for rare cancers, this is not just innovative approach. This is essential for them to access these novel precision medicines. Dr. Hope Rugo: Yeah, that is such a good point. I do think it is critical. Interestingly in breast cancer, it hasn't been, you know, there is always like two patients in these tumor-agnostic trials, or if that. You know, I think I have seen one NTRK fusion ever. I think that highlights the importance for rare cancers. And you know, I am hoping that that will translate into some new directions for some of our rarer and impossible-to-treat subtypes of breast cancer. It is this kind of research that is really going to make a difference. But what about those people who do not have biomarkers? What if you do not fit into that? Do you think there is a possibility of trying to do treatments for rare cancers in some prospective way that would help with that? You know, it is really a huge challenge. Dr. Vivek Subbiah: Absolutely. I think, you know, you're right, usually many of these rare cancers are driven by specific biomarkers. And again, some of the pediatric salivary gland tumors or pediatric sarcomas like fibrosarcomas, they are pathognomonic with NTRK fusions. And again, given that we have a tumor-agnostic approval, now these patients have access to these therapies. And I do not think that we would have had a trial just for pediatric fibrosarcomas with NTRK fusions. So that is one way. Another way is SWOG, right? The SWOG DART [1609] had this combination dual checkpoint, it was called the DART study dual combination chemotherapy with ipi/nivo. Now here the rare cancer subtype itself becomes a biomarker and they showed activity across multiple rare cancer subtypes. They didn't require a biomarker. As long as it was a rare or ultra-rare cancer, these patients were enrolled into the SWOG DART trial and multiple arms have read out. Angiosarcoma, Kaposi sarcoma, even gestational trophoblastic disease. Again, they have shown responses in these ultra-rare, rare cancers. Sometimes they might be seeing one or two cases a whole year. And I think this SWOG effort, this cooperative group effort, really highlighted the need for such studies without biomarkers as well. Dr. Hope Rugo: That is such a fantastic example of how to try and treat patients in a collaborative way. And in the paper, you also emphasize the need for collaborative research efforts, you know, uniting resource expertise across different ways of doing research. So cooperative groups, advocacy organizations that can really help advance rare cancer research, improve access to new therapies, and I think importantly influence policy changes. I think this already happened with the agnostic approvals. Could you tell us more about that? How can we move forward with this most effectively? Dr. Vivek Subbiah: Personally, I believe that collaboration is absolutely critical and essential for rare cancer research. No single institution, no single individual, or no single state or entity can tackle these challenges alone. The patient populations are small and dispersed. So pooling resources is the only way to run these meaningful trials. Again, it is not like singing, it is like putting a huge, huge, I would say, an opera piece together. It is not a solo, vocal therapy, but rather putting a huge opera piece like Turandot. You know, you mentioned cooperative groups. Cooperative groups, as I mentioned earlier, the SWOG DART program, the ASCO [TAPUR study]. ASCO is doing a phenomenal work of the TAPUR study. Again, this ASCO TAPUR program has enrolled so many patients with rare cancers who otherwise would not have treatment options. NCI-MATCH, the global effort, right? NCI-MATCH and the ComboMATCH are great examples. They bring together hundreds of sites, thousands of clinicians to run large-scale trials that would be impossible for any individual center or institution. These trials have already changed practice. For instance, the DART demonstrated the power of immunotherapy in rare cancers and influenced NCCN guidelines. One of the arms of the NCI-MATCH study from the BRAF V600E arm contributed towards the BRAF V600E tissue-agnostic approval. So, the BRAF V600E tissue-agnostic approval was by a pooled analysis of several studies. The ROAR study, the Rare Oncology Agnostic Research study, the NCI-MATCH dataset of tumor-agnostic cohort, and another pediatric trial, and also evidence from literature and evidence of case reports. And all this pooled analysis contributed to the tissue-agnostic approval of BRAF V600E across multiple rare cancers. There are several patient advocacy organizations which are the real unsung heroes here. Groups like, for instance, we mentioned in the paper, Target Cancer Foundation, don't just raise awareness for rare cancer research, they actively connect patients to trials providing financial, emotional support, and even run their own studies like the TRACK trial. They also influence policy to make access easier. On a global scale, initiatives like DRUP in the Netherlands, the ROME study in Italy, the PCM4EU in Europe are expanding precision medicine across these borders. These collaborations accelerate research, improve trial enrollment, and ensure patients everywhere can have access to these cutting-edge therapies. Again, it is truly a team effort, right? It is a multi-stakeholder approach. Researchers, clinicians, investigators, industry, regulators, academia, patients, patient advocates, and their caregivers all working together. And it takes a village. Dr. Hope Rugo: Absolutely. I mean, what a nice response to that. And I think really exciting and it is great to see your passion about this as well. But it helps all of us, I think, getting discouraged in treating these cancers to understand what is happening moving forward. And I think it is also a fabulous opportunity for our junior colleagues as they rise up in academics to be involved in these international collaborative efforts which are further expanding. One of the things that comes up for clinical trials for patients, and I think it is highlighted with rare cancers because, as you mentioned, people are all over the place, you know, they are so rare. They are all far away. Our patients are always saying to us, "Should I go here for a phase 1 trial?" Can you talk a little bit about how we can overcome these financial and geographic burdens for the patients? You talked about having trials locally, but it is a big financial and just social burden for patients. Dr. Vivek Subbiah: Great point. Financial cost is a major barrier in rare cancer clinical trials. It is a major barrier not just in rare cancer clinical trials, but in clinical trials in general. The economics of rare cancer research are one of the toughest challenges we face. Developing a new drug is already expensive, often billions of dollars. On an average, it takes 2 billion dollars or 2.8 billion dollars according to some data from drug discovery to approval. For rare cancers, the market is tiny, which means the pharmaceutical companies have really little financial incentive to invest. That is why initiatives like the Orphan Drug Act were created to provide tax credits, grants, and market exclusivity to encourage development for rare diseases. Clinical trials themselves are expensive because the small patient populations mean longer recruitment times and higher per-patient costs. Geographic dispersion, as you mentioned, for the patients adds travel, coordination. That is why we need to think out of the box about decentralized trial infrastructure so that we can mitigate some of these expenses. Complex trial designs like basket or platform trials sometimes require sophisticated data systems and regulatory oversight. That is a challenge. And I think some of the pragmatic studies like ASCO TAPUR have overcome those challenges. Advanced technologies like next-gen sequencing and molecular profiling also add significant upfront cost to this. Funding is also limited because rare cancers receive less attention compared to common cancers. Public funding and cooperative group trials help a lot, but I think they cannot cover everything. Patient advocacy organizations sometimes step in to bridge these gaps, but sustainable financing remains a huge challenge. So, the bottom line is without financial incentives and collaborating funding models, many promising therapies for rare cancers would never make it to patients. That is why we need system-wide policy changes, global partnerships, and innovative, effective, seamless trial designs which are so critical so that they can help reduce the cost and make research feasible so that we can deliver the right drug to the right patient at the right time. Dr. Hope Rugo: There is a lot of excitement about the future integration of AI in screening. Just at the San Antonio Breast Cancer meetings, we have a number of different presentations about AI to find markers, even like HER2, and using AI where you would screen and then match patients to clinical trials. Do you have any guidance for the rare cancer community on how to leverage this technology in order to optimize patient enrollment and, I think, identification of the best treatment matches? Dr. Vivek Subbiah: I think artificial intelligence, AI, is a game-changer in the making. Right now, clinical trial is clunky. Matching patients to trial is often manual, time consuming, laborious. You need a lot of personnel to do that. AI can automate this process by analyzing genomic data, medical records, and trial eligibility criteria to find the best matches quickly, accurately, and effectively. For the community, the key is to invest in data standardization and interoperability because AI needs clean, structured data to work effectively. Dr. Hope Rugo: Thank you so much, Dr. Subbiah, for sharing these fantastic insights with us on the podcast today and for your excellent article. Dr. Vivek Subbiah: Thank you so much. Dr. Hope Rugo: We thank you, our listeners, for joining us today. You will find a link to Dr. Subbiah's Educational Book article in the transcript of this episode. And please join us again next month on By the Book for more insightful views on key issues and innovations that are shaping modern oncology.  Thank you. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow today's speakers:        Dr. Hope Rugo   @hoperugo   Dr. Vivek Subbiah @VivekSubbiah Follow ASCO on social media:        ASCO on X  ASCO on Bluesky       ASCO on Facebook        ASCO on LinkedIn        Disclosures:       Dr. Hope Rugo:    Honoraria: Mylan/Viatris, Chugai Pharma   Consulting/Advisory Role: Napo Pharmaceuticals, Sanofi, Bristol Myer   Research Funding (Inst.): OBI Pharma, Pfizer, Novartis, Lilly, Merck, Daiichi Sankyo, AstraZeneca, Gilead Sciences, Hoffman La-Roche AG/Genentech, In., Stemline Therapeutics, Ambryx   Dr. Vivek Subbiah: Consulting/Advisory Role: Loxo/Lilly, Illumina, AADI, Foundation Medicine, Relay Therapeutics, Pfizer, Roche, Bayer, Incyte, Novartis, Pheon Therapeutics, Abbvie Research Funding (Inst.): Novartis, GlaxoSmithKline, NanoCarrier, Northwest Biotherapeutics, Genentech/Roche, Berg Pharma, Bayer, Incyte, Fujifilm, PharmaMar, D3 Oncology Solutions, Pfizer, Amgen, Abbvie, Mutlivir, Blueprint Medicines, Loxo, Vegenics, Takeda, Alfasigma, Agensys, Idera, Boston Biomedical, Inhibrx, Exelixis, Amgen, Turningpoint Therapeutics, Relay Therapeutics Other Relationship: Medscape, Clinical Care Options

In this episode, Rodrigo Santos, President of the Crop Science Division at Bayer, joins Andy and Tom to reflect on 2025 and look ahead to 2026. Rodrigo shares how Bayer is expanding their field organization, growing the Preceon® Smart Corn System, and leveraging digital tools to accelerate innovation. He also discusses Bayer's global farming insights from South America, the evolution of sustainability practices, and what's coming for the ForGround program. From managing legal challenges to forging stronger grower relationships, this conversation covers Bayer's multi-pronged strategy for the future of agriculture.

In der heutigen Folge sprechen die Finanzjournalisten Anja Ettel und Holger Zschäpitz über einen Ritterschlag für Intel, Rebound bei Rüstung und einen Branchen-Deal der Superlative. Außerdem geht es um Apple, Garmin, Thermo Fisher, Boston Scientific, Johnson Health Tech, Planet Fitness, Life Time, Gym Group, Basic Fit, Xponential Fitness, Technogym, Nike, Adidas, Puma, Lululemon, Lockheed Martin, L3Harris, Kratos Defense, Nvidia, Oracle, Apple, Palantir, Bayer, Puma, Tilray Brands, General Motors, Elevance Health, Centene, Cigna, UnitedHealth und Molina Healthcare, Rio Tinto, Glencore, BHP Group, Siemens, Meta und Keller Group. Wir freuen uns an Feedback über aaa@welt.de. Noch mehr "Alles auf Aktien" findet Ihr bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts und AAA-Newsletter. Hier bei WELT: https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html. Der Börsen-Podcast Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? Hier findest du alle Infos & Rabatte! https://linktr.ee/alles_auf_aktien Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

TODAY ON THE ROBERT SCOTT BELL SHOW: Fentanyl Vaccine Claims, Bayer Loses Immunity Fight, Silver Nanotech Breakthrough, Happiness Protects Health, Squilla Maritima, Seniors Overmedicated Crisis, Rep. Jennifer Wortz, Parental Rights, Anti-Property Radicalism, Caller of The Day, and MORE! https://robertscottbell.com/experimental-vaccine-claims-bayer-loses-immunity-fight-silver-nanotech-breakthrough-happiness-protects-health-squilla-maritima-seniors-overmedicated-crisis-rep-jennifer-wortz-parental-rights-a/https://boxcast.tv/view/fentanyl-vaccine-claims-bayer-loses-immunity-fight-silver-nanotech-breakthrough-rep-jennifer-wortz-parental-rights---the-rsb-show-1-6-26-as6ep4ttvjpqmfvdehb5 Purpose and Character The use of copyrighted material on the website is for non-commercial, educational purposes, and is intended to provide benefit to the public through information, critique, teaching, scholarship, or research. Nature of Copyrighted Material Weensure that the copyrighted material used is for supplementary and illustrative purposes and that it contributes significantly to the user's understanding of the content in a non-detrimental way to the commercial value of the original content. Amount and Substantiality Our website uses only the necessary amount of copyrighted material to achieve the intended purpose and does not substitute for the original market of the copyrighted works. Effect on Market Value The use of copyrighted material on our website does not in any way diminish or affect the market value of the original work. We believe that our use constitutes a 'fair use' of any such copyrighted material as provided for in section 107 of the U.S. Copyright Law. If you believe that any content on the website violates your copyright, please contact us providing the necessary information, and we will take appropriate action to address your concern.

Today's guest is Vaithi Bharath, Associate Director of Data Science & AI Solutions at Bayer. Bharath joins Emerj Editorial Director Matthew DeMello to break down why clinical R&D timelines often slip for reasons that have little to do with model performance. Rather, delays compound when data moves across fragmented systems, teams rely on slow handoffs, and validation requirements turn minor adjustments into major cycle-time hits. He walks through where decision-making slows from data capture through database lock, and what it takes to accelerate workflows without replacing a validated environment. Want to share your AI adoption story with executive peers? Click emerj.com/expert2 for more information and to be a potential future guest on the 'AI in Business' podcast! This episode is sponsored by AnswerRocket.

What happens when you discover your partner has over $400,000 in student loan debt and they didn't even know it existed?In today's audience caller episode of The Real Stuff, I'm sitting down with Brittany, a listener who bravely came on the podcast to share one of the most raw, honest, and financially transparent stories we've ever featured.Brittany opens up about putting herself through college after her parents divorced, graduating with $100,000 in student loan debt, and spending her 20s working nonstop to pay it off while attending a private university surrounded by students from much wealthier families. She had a clear financial plan for her life: get her master's degree, become debt-free before 30, and feel financially secure before starting a family… then she met her now-husband.One night, lying in bed scrolling on her phone, Brittany discovered something that completely changed the course of their relationship. The student loan debt her partner believed was around $200,000 was actually more than $400,000, and she was the one who had to uncover it, piece it together, and tell him the truth.In this episode, Brittany shares exactly how she found the debt, what it felt like to confront the person she loved most, and why this discovery shattered her sense of trust, security, and honesty in their relationship. We talk about why this wasn't just about money, but about transparency, reliability, and the emotional weight we attach to financial independence. She opens up about how she processed everything, the guilt and shame she felt for questioning her relationship because of money, and how unsupported she felt when others minimized her concerns.What makes this conversation especially powerful is Brittany's willingness to be incredibly specific. We talk REAL numbers — student loan balances, salaries, mortgage payments, rent, savings, and the sacrifices required to pay off hundreds of thousands of dollars in debt without letting it completely control their lives. Brittany also shares how navigating debt reshaped their relationship, became the foundation of their marriage, and ultimately forced them to redefine what success and happiness really look like. We also talk about family planning, having their first baby, choosing to leave a three-bedroom house with a low mortgage to live in a one-bedroom apartment in the NYC area, and why she's never been happier — proving that happiness and fulfillment don't always come from traditional financial milestones.If you've ever felt ashamed about debt, questioned a relationship because of money, or struggled to balance financial goals with actually living your life, this conversation will make you feel far less alone.Brittany has recently begun building a platform called Be Loan Wise, focused on helping others navigate the emotional and financial sides of student loan debt. You can follow along at @beloanwise on Instagram!Sponsors:Bayer: Check out Bayer's trusted lineup of products, available at Walmart, CVS, Amazon, and Walgreens.Pique: Unlock 20% off and begin your journey toward sustained wellness today at Piquelife.com/REALSTUFFWatch this episode in video form on YouTube: https://www.youtube.com/playlist?list=PLjmevEcbh5h5FEX0pazPEtN86t7eb2OgX To apply to be a guest on the show, visit luciefink.com/apply and send us your story. I also want to extend a special thank you to East Love for the show's theme song, Rolling Stone. Follow the show on Instagram: https://www.instagram.com/therealstuffpod Find Lucie here: Instagram: https://www.instagram.com/luciebfink/ TikTok: https://www.tiktok.com/@luciebfink YouTube: https://www.youtube.com/luciebfinkWebsite: https://luciefink.com/ Subscribe to my free newsletter "The Lucie List" here: https://thelucielist.beehiiv.com/subscribeSubscribe to "The Creator Confidential": http://www.luciefink.com/confidentialExecutive Producer: Cloud10Produced by Dear Media.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Choosing traits for new canola varieties goes well beyond yield, with breeders balancing disease resistance, lodging tolerance, maturity, and other agronomic needs that vary by farm and region. That approach was the focus of a conversation at Canola Week in Saskatoon, where RealAgriculture spoke with Jed Christianson, Bayer’s product design canola lead, about how Bayer... Read More

本集節目由【西谷子 力度伸接骨木莓飲+鋅】贊助播出 孩子的成長日常，就是爸媽的生活日常。 來自德國 Bayer 的「力度伸 接骨木莓＋鋅」 結合接骨木莓與鋅等營養成分 提供適合日常補充的新選擇，陪伴全家每一天

On today's show, guest host Bert Zipperer speaks with dairy journalist Pete Hardin. They recap the big stories in the agricultural industry over 2025, in an extension of their coverage on their weekly feature on WORT, The Milkweed.  Dairy and cheese production is quintessentially Wisconsin, since the time that settler farmers brought their herds to regenerate the land cleared of forests by an earlier generation of settlers. Hardin calls Wisconsin's dairy industry the greatest non-extractive economic development of the state. Now, dairy is a $50-60 billion dollar industry, with celebrated small producers like Cedar Grove and large producers like BelGioioso.  But the cheese market is terrible right now, says Hardin. Since 2024, prices have declined 30-35%. On top of declining gains for producers, immigrant farmworkers are being targeted by the Trump administration, despite the foundational role they play in the nation’s agricultural sector. The agricultural sector as a whole is struggling, from the ravages of the avian flu to the Trump administration's tariffs that hit the soybean market hard. And then there are the lawsuits against Monsanto and Bayer, the producers of the carcinogenic herbicide called glyphosate or Roundup, that the Trump administration wants to overturn. In this market, Hardin says that he's worried about hungry farmers and hungry consumers. Featured image of the Old Country Cheese plant in Cashton, Wisconsin via Rawpixel.  Did you enjoy this story? Your funding makes great, local journalism like this possible. Donate hereThe post Hungry Farmers and Hungry Consumers appeared first on WORT-FM 89.9.

Shunji Tomatsu, MD, PhD, Professor and Head, Nemours Children's Health, Delaware, USA; Alessandra d'Azzo, PhD, Emerita Faculty, Genetics, St. Jude Children's Research Hospital, Tennessee, USA; Merve Emecen Sanli, MD, Associate Professor, Department of Pediatrics, University of Texas Southwestern Medical Center, Texas, USA; and Ryan Colburn, patient with Pompe disease and president of Odimm Inc, discuss new and emerging gene therapies for lysosomal disorders.This continuing education activity is provided through collaboration between the Lysosomal and Rare Disorders Research and Treatment Center (LDRTC), CheckRare CE, and AffinityCE. This activity provides continuing education credit for physicians, physician assistants, nurses, nurse practitioners, and genetic counselors. A statement of participation is available to other attendees.To obtain CME/CE credit, please visit https://checkrare.com/learning/p-grids2025-session6-current-issues-in-gene-therapies-for-lysosomal-disorders/  Learning ObjectivesDescribe current and emerging gene therapy data in lysosomal disorders and its clinical relevanceDescribe role of patients in gene therapy developmentFacultyShunji Tomatsu, MD, PhD, Professor and Head, Nemours Children's HealthAlessandra d'Azzo, PhD, Emerita Faculty, Genetics, St. Jude Children's Research HospitalMerve Emecen Sanli, MD, Associate Professor, Department of Pediatrics, University of Texas Southwestern Medical CenterRyan Colburn. Odimm, Inc.DisclosuresAffinityCE staff, LDRTC staff, planners, and reviewers, have no relevant financial relationships with ineligible companies to disclose. Faculty disclosures, listed below, will also be disclosed at the beginning of the Program.Shunji Tomatsu, MD, PhD Dr. Tomatsu has received the following grants: Morquio Foundations and families: Scarlett Grifith, Bennett, A Cure for Roberts, and Morquio Conference; MPS Societies: Japanese, National, and Austrian; NIH grants: 1-R01-HD102545, NIH, NICHD, Tomatsu (PI), 1R01HD104814-01A1, NIH, NICHD, Langan, T.J. (PI), Role: Site-PI, R43HD114328-01, NIH, ACOSTA, WALTER (PI), Role: site PI, 1R43AR084638-01, NIH, MOUNZIH, KHALID (PI); Foundation of NIH: FNIH RFP NUMBER: 2022-BGTC-005 Tomatsu (PI). Alessandra d'Azzo, PhDDr. D'Azzo has no relevant financial relationships to disclose.Merve Emecen Sanli, MDDr. Sanli has no relevant financial relationships to disclose.Ryan ColburnMr. Colburn has an advisory, consulting and/or project based relationship or stock holding with: Abeona Therapeutics, Amicus Therapeutics, Astellas Gene Therapies, Avidity Biosciences, Bayer, Catalyst Pharmaceuticals, Denali Therapeutics, M6P Therapeutics, Sangamo Therapeutics, Sanofi, Solid Biosciences.Mitigation of Relevant Financial RelationshipsAffinityCE adheres to the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity. Conflicts of interest for presenting faculty with relevant financial interests were resolved through peer review of content by a non-conflicted reviewer.Accreditation and Credit DesignationPhysiciansThis activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and the LDRTC. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.AffinityCE designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.Physician AssistantsAffinityCE designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credits™. Physician Assistants should claim only the credit commensurate with the extent of their participation in the activity.NursesAffinityCE is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation (ANCC). This activity provides a maximum of 1 hours of continuing nursing education credit.Nurse PractitionersAffinityCE designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credits™. Nurse practitioners should claim only the credit commensurate with the extent of their participation in the activity.Genetic CounselorsAffinityCE designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credits™. Genetic Counselors should claim only the credit commensurate with the extent of their participation in the activity.Other ProfessionalsAll other health care professionals completing this continuing education activity will be issued a statement of participation indicating the number of hours of continuing education credit. This may be used for professional education CE credit. Please consult your accrediting organization or licensing board for their acceptance of this CE activity. Participation CostsThere is no cost to participate in this activity.CME InquiriesFor all CME policy-related inquiries, please contact us at ce@affinityced.comSend customer support requests to cds_support+ldrtc@affinityced.com

Silvester unterm Kreuz, was bietet sich da also mehr an als der Blick nach vorne auf das anstehende Jahr 2026? Lara, Nils, Pippo und Kevin haben jeweils eine These für das Bayer-04-Jahr mitgebracht, die eine gewagter, die andere etwas vorsichtiger und geben sie zum Besten. Von Tabellenführung, Titel, Transfers und Verbleib ist alles dabei. Ende 2026 werden wir diese dann auflösen. Schreibt uns gerne eure Thesen über unsere Social-Media-Kanäle, dann werden wir die auch in die Analyse einbeziehen. Habt einen guten Rutsch ins neue Jahr, bleibt gesund und auf erfolgreiche Spiele und vielleicht eine gemeinsame Reise nach Berlin im Mai? Das wär doch ...Dieser Podcast wird vermarktet von der Podcastbude.www.podcastbu.de - Full-Service-Podcast-Agentur - Konzeption, Produktion, Vermarktung, Distribution und Hosting.Du möchtest deinen Podcast auch kostenlos hosten und damit Geld verdienen?Dann schaue auf www.kostenlos-hosten.de und informiere dich.Dort erhältst du alle Informationen zu unseren kostenlosen Podcast-Hosting-Angeboten. kostenlos-hosten.de ist ein Produkt der Podcastbude.

Bayer Crop Science's seed production plants play a critical role in ensuring the performance farmers expect from DEKALB® corn and Asgrow® soybeans.In this Managing for Profit, Clint Rodenberg, production lead for DEKALB brand, and Drew Yingling, plant production manager at Bayer's Stonington, Illinois, Asgrow soybean production facility, share how the process starts long before farmers ever open a bag of seed.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Jaciara is a transracial/international adoptee. She was adopted from Brazil in 1985 when she was 11 months old and raised in Northern California by a Jewish single parent mother, in a small and very minimally diverse town. Jaciara has obtained her Master's degree in Social Work and her bachelor's degree in Psychology. She currently works as a medical social worker in a hospital and has been in this field for many years. Jaciara has also worked in the field of adoption/foster care at various capacities for 10 years, and recently has begun a new part-time role as a Court Appointed Family Engagement Specialist. She has been a panelist on numerous adult adoptee panels, has co-developed and presented training curriculum utilizing both her lived and professional experience on the multi-layered experiences and nuances in transracial placement/adoption. She has also created educational curriculum for adoptee youth teaching mindfulness practices, as well as sharing learned life lessons and hardships from her lived experience in effort to provide the support and knowledge she so greatly wished to have had when she was younger. Jaciara has also independently provided 1:1 mentorship primarily to teenage adoptees including extending support/guidance to their adoptive parent(s). Jaciara is a member of the Board of Directors for S.P.A.C.E. (School of Performing Arts and Cultural Education) a well-known organization in her hometown that she actively participated in as a youth; she holds the position as the Chair of the board's Cultural Education Committee. Outside of her professional work, her most cherished and beloved hobby is Samba dance; and she is a principal dancer on a award winning Samba team. For Jaciara, Samba has been her most steady connection to her Afro-Brazilian roots.Resources/References: https://youtu.be/dmfxulaeMZI?si=exMTT3VX9SZkqXuB http://www.radiocurious.org/2015/03/31/bayer-jaciara-jaciara-bayer-transracial-adoptions-and-white-privilege/ https://www.patreon.com/c/adopteelandMusic by Corey Quinn

Drs Harrington and Gibson's annual review of cardiovascular medicine: ACS guidelines, antiplatelet management, GLP-1s, and ever lower LDL-C with drugs or even gene editing are among the highlights. This podcast is intended for healthcare professionals only. To read a transcript or to comment, visit https://www.medscape.com/author/bob-harrington New ACS Guidelines 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes https://doi.org/10.1161/CIR.0000000000001309 ACS Guideline Chair and Vice-Chair Discussion https://www.medscape.com/viewarticle/acs-guidelines-2025-key-points-chair-and-vice-chair-2025a100093l Antiplatelet/Antithrombotic Strategies Prasugrel Beats Ticagrelor in High-Risk Patients With Diabetes After PCI https://www.medscape.com/viewarticle/prasugrel-beats-ticagrelor-high-risk-patients-diabetes-after-2025a1000wbt Early Withdrawal of Aspirin after PCI in Acute Coronary Syndromes (NEO-MINDSET) https://www.nejm.org/doi/full/10.1056/NEJMoa2507980 Aspirin in Patients with Chronic Coronary Syndrome Receiving Oral Anticoagulation (AQUATIC) https://www.nejm.org/doi/full/10.1056/NEJMoa2507532 Bayesian Machine Learning Model Guiding Iterative, Personalized Anticoagulant Dosing Decision-Making : ENGAGE AF-TIMI 48 Trial Analysis https://doi.org/10.1016/j.jacadv.2025.102504 Factor XI Inhibitors Bristol Myers, J&J Stop Blood Clotting Drug Trial After Interim Review https://www.medscape.com/s/viewarticle/bristol-myers-j-j-stop-blood-clotting-drug-trial-after-2025a1000vqu Bayer's Asundexian Met Primary Efficacy and Safety Endpoints in Landmark Phase III OCEANIC-STROKE Study in Secondary Stroke Prevention https://www.bayer.com/en/us/news-stories/oceanic-stroke OAC-Naive Subgroup From OCEANIC-AF Published https://www.medscape.com/viewarticle/novel-blood-thinner-shows-promise-atrial-fibrillation-2025a10008lz GLP-1 and Myotrophic Drugs Lilly's Next-gen Drug Shows Greater Weight Loss Than Zepbound in Late-stage Trial (TRIUMPH-4) https://www.medscape.com/s/viewarticle/lillys-next-gen-drug-tops-zepbound-weight-loss-late-stage-2025a1000ys1 Amylin Analog Eloralintide Reduces Weight in Phase 2 Trial https://www.medscape.com/viewarticle/amylin-analog-eloralintide-reduces-weight-phase-2-trial-2025a1000uqf CRISPR and Lipid Lowering Patient-Specific In Vivo Gene Editing to Treat a Rare Genetic Disease https://www.nejm.org/doi/full/10.1056/NEJMoa2504747 Gene Therapy Shows Lipid Improvement but Raises Flags https://www.medscape.com/viewarticle/gene-therapy-shows-lipid-improvement-raises-flags-2025a1000uzw Phase 1 Trial of CRISPR-Cas9 Gene Editing Targeting ANGPTL3 https://www.nejm.org/doi/full/10.1056/NEJMoa2511778 Evolocumab in Patients without a Previous Myocardial Infarction or Stroke (VESALIUS-CV) https://www.nejm.org/doi/pdf/10.1056/NEJMoa2514428 Prehospital GLP IIb/IIIa Zalunfiban at First Medical Contact for ST-Elevation Myocardial Infarction (CELEBRATE) https://evidence.nejm.org/doi/full/10.1056/EVIDoa2500268 You may also like: Hear John Mandrola, MD's summary and perspective on the top cardiology news each week, on This Week in Cardiology https://www.medscape.com/twic Questions or feedback, please contact news@medscape.net

Hermann Haller, MD, PhD President, Professor, MDI Biological Laboratory; Professor, Department of Nephrology and Hypertension, Hannover Medical School Haller received his medical degree from the Free University of Berlin and completed his postdoctoral work at Yale University. He has published more than 700 peer-reviewed articles, holds six world-wide patents and has founded four biotech companies. He has received many honors and awards and serves on numerous advisory boards, including those of Bayer, Boehringer Ingelheim, Genzyme and Novo Nordisk. In addition to his position at the MDI Biological Laboratory, he is also a full professor of medicine and former chairman of the Division of Nephrology at the Hannover Medical School in Germany. INNOVATORS is a podcast production of Harris Search Associates.      *The views and opinions shared by the guests on INNOVATORS do not necessarily reflect the views of the interviewee's institution or organization.*

We wrap the week with more NAFB Trade Talk conversations recorded a few weeks ago between Chip Flory and several guests: Daryl Theis of Claas on forage harvesting, Deena Hardie of Merck Animal Health on parasite and BRD management, Jarod Jacobs of ForGround by Bayer with a carbon update, Brady Spangenberg of BASF on crop protection, and Lynn Justesen of UPL.See omnystudio.com/listener for privacy information.

No último A HORA DO CONSOLO de 2025:  Daniel Bayer e João Carvalho resolvem problemas cabeludos de ouvintes traídos, ateus e namoradores de casadas.FINANCIE ESTE VACILO:apoia.se/decrepitosAssine o plano BOGA VIVA e participe do nosso GRUPO SECRETO NO TELEGRAM!MANDA PIX:livepix.gg/decrepitosPARTICIPE PELO E-MAIL:ouvinte@decrepitos.comANUNCIE COM A GENTE:comercial@decrepitos.com© Copyright 2025 - Decrépitos Podcast

Bayer has long been known as a leader in seed and trait innovation. In this episode of Managing for Profit, Connie Davis, Product Development Scientist for Bayer Crop Science, talks about how Bayer's commitment to innovation is transforming how new technologies reach farmers.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Der Dax erlebte ein Jahr voller Schwankungen und Rekorde. Unternehmen waren mit globalen und lokalen Herausforderungen konfrontiert. Wie wird es 2026 weitergehen?

Die Bundesliga macht Winterpause und wir nutzen den Rückblick auf den 15. Spieltag für eine kleine Bilanz: Wer waren Spieler, Trainer und Fans des Halbjahres? Jens und Alex bauen sich den „perfekten“ Club der vergangenen Monate. Dabei schauen wir natürlich auch auf die Highlights des 15. Spieltags zurück. Ist Harry Kane aktuell sogar der beste Stürmer Europas? Mit seinem Tor beim Sieg des FC Bayern München in Heidenheim erreichte er die unglaubliche Marke von 100 Torbeteiligungen in der Bundesliga – im gerade mal 78. Spiel. Borussia Dortmund bleibt sich auch zum Ende des Jahres 2025 treu: das Spiel gegen Borussia Mönchengladbach ist nicht spektakulär aber erfolgreich. Statistisch sticht dabei Nico Schlotterbeck erneut heraus. Ist er aktuell der beste Dortmunder? Und wer sticht bei RB Leipzig und Bayer Leverkusen heraus? Bayer gewinnt das Topspiel ohne seine Africa-Cup-Stars auf überzeugende Art und Weise. Deutlich weniger Spektakel gab es auf diversen anderen Plätzen – drei Mal 0:0 bei Stuttgart gegen Hoffenheim, Augsburg gegen Werder und Mainz gegen St. Pauli. Es schaffen trotzdem Spieler der Teams in den „perfekten“ Club des Halbjahres von Alex und Jens. Und wer ist von Eintracht Frankfurt, die sich auf der letzten Rille gegen den HSV zum Remis gemüht hat, dabei? Von den Hamburgern hat sich zum Beispiel mal wieder Luka Vuskovic in den Vordergrund gespielt. Wird er in einem „perfekten“ Team stehen? Die Antworten auf diese Fragen gibt es in der aktuellen Folge des Bundesliga Updates. Viel Spaß beim Hören – und vielen Dank fürs Dabei sein! Habt alle schöne und erholsame Weihnachtstage und startet gut ins Jahr 2026!

Kontrovers, unterhaltsam, meinungsbildend – mit Sky90 präsentiert Sky den umfassendsten Fußball-Live-Talk Deutschlands. Immer sonntags ab 18:00 Uhr begrüßt Moderator Patrick Wasserziehr kompetente Gäste im Sky Studio. Michael Reschke: u.a. ehemaliger technischer Direktor von Bayer 04 Leverkusen und Bayern München, aktuell Europachef der Berateragentur ICM Stellar Valentina Maceri: Moderatorin Steffen Freund: Europameister 1996 und Champions League Sieger mit dem BVB 1997 Didi Hamann: Sky-Experte und Champions League Sieger Themen: -Nach der Sammer-Kritik: Diffuse Unruhe – die komplizierte Wirklichkeit beim BVB -Das Spiel der Kovac-Elf gegen Borussia M´gladbach ist richtungsweisend -Viertes Pflichtspiel für Urs Fischer – Mainz gegen St. Pauli - das berühmte 6-Punkte Spiel -Duell der Gegensätze - Heidenheim empfängt den Rekordmeister aus München -Hinrunden-Fazit der Saison 2025/2026

Infective endocarditis is a rare but life threatening infection of the heart, specifically the endocardium. We look at what causes infective endocarditis, its signs and symptoms, as well as diagnosis (including dukes criteria for infective endocarditis) and treatment.PDFs available here: https://rhesusmedicine.com/pages/cardiologyConsider subscribing (if you found any of the info useful!): https://www.youtube.com/channel/UCRks8wB6vgz0E7buP0L_5RQ?sub_confirmation=1Buy Us A Coffee!: https://www.buymeacoffee.com/rhesusmedicineTimestamps:0:00 What is Infective Endocarditis? (Definition) 0:15 Infective Endocarditis Pathophysiology 1:45 Infective Endocarditis Complications3:05 Infective Endocarditis Signs and Symptoms4:20  Infective Endocarditis Risk Factors (Causes) 5:19 Which microorganisms cause infective endocarditis? 6:02 Infective Endocarditis Epidemiology6:45 Infective Endocarditis Diagnosis (Duke Criteria)8:08 Infective Endocarditis Treatment LINK TO SOCIAL MEDIA: https://www.instagram.com/rhesusmedicine/ReferencesHolland, T.L., Baddour, L.M., Bayer, A.S., Hoen, B. & Miro, J.M., 2016. Infective endocarditis. Nature Reviews Disease Primers, 2:16059. [online] Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5240923/. PubMed CentralWikipedia, 2025. Infective endocarditis. [online] Available at: https://en.wikipedia.org/wiki/Infective_endocarditis. WikipediaRajani, R. & Klein, J.L., 2020. Infective endocarditis: A contemporary update. Clinical Medicine, 20(1), pp.31-35. [online] Available at: https://www.rcpjournals.org/content/clinmedicine/20/1/31. OvidRazmi, R. & Magnusson, P., 2019. Introductory chapter: Infective endocarditis – An introduction. In: Infective Endocarditis. IntechOpen. [online] Available at: https://www.intechopen.com/chapters/45210. ResearchGateNational Organization for Rare Disorders (NORD), 2024. Endocarditis, infective. [online] Available at: https://rarediseases.org/rare-diseases/endocarditis-infective/. National Organization for Rare DisordersDisclaimer: Please remember this podcast and all content from Rhesus Medicine is for educational and entertainment purposes only and is not a guide to diagnose or to treat any form of condition. The content is not to be used to guide clinical practice and is not medical advice. Please consult a healthcare professional for medical advice.

On this episode of The Mark White Show, Dr. Diana Bitner, board certified OB GYN and Certified Menopause Society Practitioner, joins veteran news anchor and patient advocate Wendee Lee Curtis for an open conversation about moderate to severe hot flashes due to menopause. They discuss what these symptoms can feel like, why many women are unprepared for their impact, and the importance of talking with a healthcare professional. The conversation also includes information about Lynkuet® (elinzanetant), a newly FDA approved, hormone free treatment option for moderate to severe hot flashes due to menopause. This episode focuses on awareness, understanding, and informed conversations between women and their doctors. These guests appear on behalf of Bayer and have been compensated for their time.

In Episode 33, Dr. Aly-Khan Lalani and Dr. Christoper Wallis sit down with Dr. Daniel Heng, Clinical Professor at the University of Calgary and Head of Medical Oncology at the Arthur J.E. Child Comprehensive Cancer Centre. Together, they explore the full landscape of mentorship and sponsorship in academic medicine, from what makes an exceptional mentee to how leaders identify and support rising talent.The View on GU with Lalani & Wallis integrates key clinical data from major conferences and high impact publications, sharing meaningful take home messages for practising clinicians in the field of genitourinary (GU) cancers. Learn more about The View on GU: theviewongu.caThis podcast has been made possible through unrestricted financial support by Novartis, Bayer, Astellas, Tolmar, Ipsen, J&J, Merck, Pfizer, Eisai and AbbVie.

100 Tage Kasper Hjulmand in Leverkusen, 100 Tage Entwicklung, 100 Tage ein neues Gefühl unterm Kreuz. Nils, Lara und Kevin haben sich für diese Ausgabe wieder mit Pippo Arens verstärkt, gemeinsam spricht das Quartett über die letzten Auftritte in Liga, Champions League und Pokal, aber auch über das Formbarometer der Mannschaft. Die Mentalität, das Teamgefüge, die Schlüsselspieler und eine Aussicht auf das, was daraus entstehen kann. Das alles in knapp 100 Minuten BayPod. Das gesamte Team wünscht euch bereits jetzt schöne Weihnachtsfeiertage. Genießt die Zeit, das gute Essen und hoffentlich kriegen wir als Geschenk am Wochenende nochmal einen Sieg vom Bayer. Wir hoffen, ...Dieser Podcast wird vermarktet von der Podcastbude.www.podcastbu.de - Full-Service-Podcast-Agentur - Konzeption, Produktion, Vermarktung, Distribution und Hosting.Du möchtest deinen Podcast auch kostenlos hosten und damit Geld verdienen?Dann schaue auf www.kostenlos-hosten.de und informiere dich.Dort erhältst du alle Informationen zu unseren kostenlosen Podcast-Hosting-Angeboten. kostenlos-hosten.de ist ein Produkt der Podcastbude.

Today's guest is Kun He, Lead Scientific Advisor at Bayer Crop Science. He joins Emerj Editorial Director Matthew DeMello to discuss how AI is transforming human talent and workforce development in agricultural manufacturing, balancing data-driven efficiency with the irreplaceable role of human gut instinct. Kun also explores practical takeaways, such as integrating genotyping and phenotyping data to accelerate crop-breeding workflows, empowering breeders to drive "step change" innovations, and treating AI as a co-pilot to check biases while prioritizing customer needs for blockbuster R&D outcomes. Want to share your AI adoption story with executive peers? Click emerj.com/expert2 for more information and to be a potential future guest on the 'AI in Business' podcast!

Der deutsche Chemiekonzern hat sich mit dem Kauf von Monsanto milliardenschwere Klagen aufgehalst. Doch mittlerweile zeigt sich auch, welche Macht Bayer damit erhalten hat.

S5E13 Future of AI-Powered Consumer Insights with Trevor Sumner & Stan SthanunathanIn Season 5, Episode 13 of The Retail Razor Show, hosts Ricardo Belmar and Casey Golden tackle one of retail's biggest blind spots in consumer insights: the consumer sentiment gap. For decades, brands relied on surveys to understand shoppers. But what people say doesn't always match what they do.Enter AI-powered shopper insights!Joining the conversation are Trevor Sumner (CEO of i-Genie AI) and Stan Sthanunathan (Executive Chairman of i-Genie AI, former EVP at Unilever and VP at Coca-Cola). Together, they reveal how billions of unfiltered signals — from searches, reviews, and social posts — can be transformed into real-time, actionable consumer insights that reshape retail decision-making.What You'll Learn in This Episode:Why traditional consumer surveys are breaking downHow AI and natural language processing uncover real customer behaviorThe role of empathy vs sympathy in understanding consumersHow disruptor brands are reshaping competitive landscapesWhy augmented intelligence (AI + human insight) is the future of retail strategy and consumer insightsSubscribe to the Retail Razor Podcast Network: https://retailrazor.com/Subscribe to our Newsletter: https://retailrazor.substack.comSubscribe to our YouTube channel: https://bit.ly/RRShowYouTubeAbout our GuestsTrevor Sumner, CEO, i-Genie.AI - https://www.linkedin.com/in/trevorsumner/Trevor is a NYC-based entrepreneur, product and marketing executive and recognized startup advisor and angel. Trevor is the CEO at i-Genie.ai, the leading AI platform for consumer insights, revolutionizing an industry that had been dominated with antiquated survey methodologies by synthesizing tens of billions of searches, social and video posts, ratings and reviews and market data for industry leaders like Kenvue, Unilever, Coca-Cola, Bayer, Clorox and more.Previously, Mr. Sumner was Head of AI and Data Platform products for Raydiant, a leading VC-backed digital experience platform that is transforming over 250,000 digital touch points across 4,500 clients with AI, computer vision and data.Mr. Sumner came to Raydiant when it acquired Perch, a recognized leader in in-store Product Engagement Marketing, interactive retail displays and augmented reality, where Mr. SUmner served as CEO. Perch was named a Top Tech Company to Watch by Forbes, a Top 10 Retail Technology company by CIO Review and has won numerous Clio, Fast Company, Edison, Bloomberg and Digi awards.Stan Sthanunathan, Executive Chairman, i-Genie.AI - https://www.linkedin.com/in/stan-sthanunathan-1ab4035/Stan Sthanunathan joined Unilever in July 2013 as Executive Vice President of Consumer & Market Insights. As chief provocateur, he headed up the insights function globally based in London. He retired from Unilever on June 1, 2021.Post retirement he has started an AI/ML enabled company called i-Genie.AI focused on delivering near real time insights and ideas to help business identify Next Big Thing. Prior to joining Unilever, he was Vice President of Marketing Strategy & Insights for The Coca-Cola Company in Atlanta, heading up the function on a global basis.Stan co-authored a paper on Building an Insights Engine that was published in Harvard Business Review, Sept 2016. He has also co-authored a book titled AI for Marketing and Product Innovation.He was awarded Lifetime Achievement award at TMRE 2022 event.Chapters:00:00 Previews 01:23 Show Intro 04:43 The Consumer Sentiment Gap 05:37 Welcome Trevor Sumner & Stan Sthanunathan 06:30 Backgrounds of Trevor and Stan 09:11 Challenges in Understanding Consumers 16:58 The Evolution of Influencers 18:32 Limitations of Surveys and the Need for AI 25:46 Augmented Intelligence: AI + Human Insight 31:46 Challenges in CPG Innovation 33:02 Innovate: A Data-Driven Product 34:42 AI and Predictive Analytics 36:21 Democratizing Data Access 38:07 Mindset Shift for Rapid Actions 40:46 Adopting AI in CPG 48:16 Retailers and Data Utilization 52:59 Future of Brand Understanding 57:23 Conclusion and Contact Information 58:15 Show CloseMeet your hosts, helping you cut through the clutter in retail & retail tech:Ricardo Belmar is an NRF Top Retail Voices for 2025 & a RETHINK Retail Top Retail Expert from 2021 – 2025. Thinkers 360 has named him a Top 10 Retail, & AGI Thought Leader, a Top 50 Management, Transformation, & Careers Thought Leader, a Top 100 Digital Transformation & Agentic AI Thought Leader, plus a Top Digital Voice for 2024 and 2025. He is an advisory council member at George Mason University's Center for Retail Transformation, and the Retail Cloud Alliance. He was most recently the director partner marketing for retail & consumer goods in the Americas at Microsoft.Casey Golden, is CEO of Luxlock, a RETHINK Retail Top Retail Expert from 2023 - 2025, and a Retail Cloud Alliance advisory council member. Obsessed with the customer relationship between the brand and the consumer. After a career on the fashion and supply chain technology side of the business, now slaying franken-stacks and building retail tech! Currently, Casey is the North America Leader for Retail & Consumer Goods at CI&T.Includes music provided by imunobeats.com, featuring Overclocked, and E-Motive from the album Beat Hype, written by Heston Mimms, published by Imuno.

Pepe Baynat analiza en Radio Intereconomía la situación general de los mercados. En el plano macro, destaca el buen momento del IBEX 35 en máximos históricos, que continúa con la tendencia alcista que viene marcando este año, mostrando fortaleza frente a otros mercados europeos. En Wall Street, pese a las caídas puntuales del sector tecnológico, el S&P 500 sigue mostrando una estructura sólida y podría volver a testear máximos si mantiene los soportes clave. Pepe Baynat insiste en la importancia de identificar soportes, resistencias y tendencias antes de tomar decisiones, señalando que muchos valores han subido con fuerza y pueden estar en fases de consolidación o corrección. El experto recomienda cautela en acciones que han tenido fuertes revalorizaciones (como Leonardo o McKesson) y advierte del riesgo de “arranques en falso” en compañías que vienen de caídas muy profundas, como Bayer, Stellantis o Nokia, donde pueden darse rebotes técnicos pero con alta volatilidad. Para estrategias de medio y largo plazo, sugiere paciencia en valores castigados pero con potencial de recuperación, como Cellnex, siempre que respeten ciertos niveles técnicos. En otros casos, plantea operaciones de corto plazo muy condicionadas a stops claros. El mercado sigue ofreciendo oportunidades, pero exige disciplina, gestión del riesgo y no dejarse llevar únicamente por subidas recientes o movimientos emocionales.

In der Folge #317 eures TrotzdemHier-Podcast am Mikrofon: * Marco (@ruhrpott-hennes) * Eric (@hibarian) * Daniel (@beffenstaumgart) Chaptermarks: 00:00:00 Intro 00:00:59 Begrüßung 00:03:01 Bayer 04 - FC 00:52:47 Nacktkontrollen und immer wieder Bayer 04 01:08:03 Ausblick FC - FC Union Baumgart 01:24:56 U19 - Pokal verschoben, Youth League gegen Inter 01:26:58 Saisonspende beide Wochen 01:37:01 Abmoderation Viel Spaß beim Hören! Den Podcast unterstützen und Familymember werden: www.trotzdemhier.de/spenden oder per Einmal-Spende via Paypal: family@trotzdemhier.de Intromusik: Sascha Brinkmann Folgt uns auf BlueSky oder Insta (Handle jeweils /TrotzdemHier) und rezensiert uns bei iTunes & Co. Jetzt auch wieder live auf Twitch: www.twitch.tv/trotzdemhierpodcast Das Team TdH: * Daniel (@beffenstaumgart) * Denis (@kylennep) * Eric (@hibarian) * Marco (@ruhrpott-hennes) * Raik (@effzehHH) * Saskia (@quarkbaellchen)

Bayer Leverkusen schlägt den FC im Derby verdient. Die TSG Hoffenheim mausert sich zum CL-Kandidaten. Eintracht Frankfurt gewinnt zwar, überzeugt aber nicht. Wolfsburg schlägt Gladbach und St. Pauli holt wichtige Zähler im Abstiegskampf!

In der heutigen Folge sprechen die Finanzjournalisten Daniel Eckert und Lea Oetjen über einen Dämpfer für Thyssenkrupp, einen Rekord für den Silberpreis und den wohl größten Börsengang aller Zeiten. Außerdem geht es um Bayer, Rheinmetall, Renk Group, Hensoldt, Applovin, Warner Bros. Discovery, Mercedes-Benz, Fidelity, Alphabet, Nvidia, BMW, Campbell Soup Company, The Trade Desk, iShares MSCI USA ETF (WKN: A0YEDU), Vanguard S&P 500 ETF (WKN: A2PFN2), iShares Edge MSCI USA, Momentum Factor ETF (WKN: A2AP36), Xtrackers MSCI World Momentum (WKN: A1103G) und SPDR MSCI World ETF (WKN: A2N6CW). Die aktuelle "Alles auf Aktien"-Umfrage findet Ihr unter: https://www.umfrageonline.com/c/mh9uebwm Wir freuen uns an Feedback über aaa@welt.de. Noch mehr "Alles auf Aktien" findet Ihr bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts und AAA-Newsletter.[ Hier bei WELT.](https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html.) [Hier] (https://open.spotify.com/playlist/6zxjyJpTMunyYCY6F7vHK1?si=8f6cTnkEQnmSrlMU8Vo6uQ) findest Du die Samstagsfolgen Klassiker-Playlist auf Spotify! Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? [**Hier findest du alle Infos & Rabatte!**](https://linktr.ee/alles_auf_aktien) Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

Erfahre hier mehr über unseren Partner Scalable Capital - dem Broker mit einem der besten YouTube-Kanäle zu Aktien & Investments.  BMW hat neuen CEO. NVIDIA hat neue Exportrechte (oder auch nicht). Robert Gagliardi hat paar Millionen mehr. Bayer performt, Evotec & Thyssenkrupp nicht. EssilorLuxottica leidet unter Google-Konkurrenz. Ares goes S&P 500. Medline goes IPO. OpenAI goes focus. Was passt besser zu Weihnachten als Schoko- & Lebensmittel? Lindt (WKN: 859568) & Coca Cola (WKN: 850663) haben die richtige Strategie. Mondelēz (WKN: A1J4U0) & Nestlé (WKN: A0Q4DC) haben's nicht so leicht. Coca-Cola Consolidated (WKN: 860150) boomt. Diesen Podcast vom 10.12.2025, 3:00 Uhr stellt dir die Podstars GmbH (Noah Leidinger) zur Verfügung.

“ It's like a group of misfits gathering behind the bleachers after school. And we're all weird and no one wants to hang out with us. So we get together and we tell stories together.” This episode features Bryce Bayer who played Munkustrap in the 2025 Music Theatre Heritage production of CATS in Kansas City. Bryce shares insights on his unique experience with this non-traditional version, including the use of minimal characters, a hip-hop and jazz infusion, and the fascinating concept of a ritualistic book club. Learn about Bryce's journey from no prior CATS experience to embracing and performing in this innovative interpretation. 03:01 The Unique 2025 Production of Cats 05:24 Rehearsal Insights and Podcast Discovery 08:09 Character Dynamics and Conceptual Approach 33:30 Creative Interpretations 36:04 Excitement for Traditional and Non-Traditional Productions 39:14 Innovative Stage Design and Props 43:02 Rapid Fire Check out Bryce on Instagram: @bbayer7 Check out MTH on Social Media: @MTHTheater ⁠⁠⁠ Check out MTH's website: ⁠musictheaterheritage.com⁠ Check out The Music Man on Tour: themusicmantour.com Produced by: ⁠⁠⁠⁠⁠⁠Alan Seales⁠⁠⁠⁠⁠⁠ & ⁠⁠⁠⁠⁠⁠Broadway Podcast Network⁠⁠⁠⁠⁠⁠ Social Media: @⁠⁠⁠⁠⁠⁠TheWrongCatDied Learn more about your ad choices. Visit megaphone.fm/adchoices

LISTEN and SUBSCRIBE on:Apple Podcasts: https://podcasts.apple.com/us/podcast/watchdog-on-wall-street-with-chris-markowski/id570687608 Spotify: https://open.spotify.com/show/2PtgPvJvqc2gkpGIkNMR5i WATCH and SUBSCRIBE on:https://www.youtube.com/@WatchdogOnWallstreet/featured  The administration is rolling out another $12 billion in “Farm Aid”, supposedly to help farmers hurt by the ongoing trade war—yet most of that cash, just like in 2018 and 2019, is poised to flow straight through the farmers and into the pockets of Big Ag giants like Bayer and Monsanto. With China falling far short of its promised soybean purchases and America doubling down on the same broken agricultural policies—ethanol mandates, corporate consolidation, and subsidizing bad incentives—we're once again treating symptoms instead of fixing the system. From misguided crop priorities to farmland mismanagement, Chris calls out the waste, the politics, and the corporations cashing in while taxpayers foot the bill.

In der heutigen Folge sprechen die Finanzjournalisten Daniel Eckert und Lea Oetjen über den Magnum-Börsengang, ein Kursfeuerwerk bei Wave Life und das große Warten auf die Fed-Sitzung. Außerdem geht es um Unilever, Klöckner & Co, Worthington Steel, Rheinmetall, Renk, Thyssenkrupp Marine Systems, Bayer, Confluent, IBM, Marvell Technology, Carvana, Nvidia, Warner Bros Discovery, Netflix, Paramount Skydance, RTL Group, Evonik Industries, Freenet, Ströer, BASF, iShares S&P 500 Communication Sector ETF (WKN: A2JQ2H) und Xtrackers MSCI USA Communication Services ETF (WKN: A2QGNF). Folgt ihr uns schon bei Instagram? Wenn nicht, könnt ihr das hier nachholen: www.instagram.com/alles_auf_aktien Die aktuelle "Alles auf Aktien"-Umfrage findet Ihr unter: https://www.umfrageonline.com/c/mh9uebwm Wir freuen uns an Feedback über aaa@welt.de. Noch mehr "Alles auf Aktien" findet Ihr bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts und AAA-Newsletter.[ Hier bei WELT.](https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html.) [Hier] (https://open.spotify.com/playlist/6zxjyJpTMunyYCY6F7vHK1?si=8f6cTnkEQnmSrlMU8Vo6uQ) findest Du die Samstagsfolgen Klassiker-Playlist auf Spotify! Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? [**Hier findest du alle Infos & Rabatte!**](https://linktr.ee/alles_auf_aktien) Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

Dr. Pedro Barata and Dr. Ravin Garg discuss strategies to increase trial representation, including leveraging trial navigators and prioritizing pragmatic trial models, as featured in the ASCO Educational Book article, "Practical Guide to Clinical Trial Accessibility: Making Trial Participation a Standard of Care." TRANSCRIPT Dr. Pedro Barata: Hello, and welcome to By the Book, a podcast from ASCO featuring compelling perspectives from authors and editors of the ASCO Educational Book. I'm Dr. Pedro Barata. I am a medical oncologist at University Hospital Seidman Cancer Center and an associate professor of medicine at Case Western Reserve University in Cleveland, Ohio. I am also the associate editor of the ASCO Educational Book. We know that in recent years, the oncology community has increasingly prioritized the need to modernize clinical trial eligibility, reduce patient burden, and enhance diversity in trial participation. On that note, today we will be speaking about ways to enhance access to clinical trials with Dr. Ravin Garg. He is a hematologist oncologist at Maryland Oncology Hematology and also an assistant professor of oncology at Johns Hopkins Hospital in Baltimore. Dr. Garg is also the co-author of a fantastic paper in the ASCO Educational Book titled, "Practical Guide to Clinical Trial Accessibility: Making Trial Participation a Standard of Care."  Dr. Garg, welcome. Thanks for being here, and congrats on your paper. Dr. Ravin Garg: Thank you for having me, Pedro. I am excited to be here. Dr. Pedro Barata: [KI1]  Your paper is a wonderful, multidisciplinary piece that actually features perspectives from the different stakeholders, right? The patient advocacy, industry, community practice, and academia about these challenges in making trials more available. This podcast is a wonderful platform. It reaches out to a lot of folks within our community. So, I will start by asking you the obvious. Why do you think it is a must read for our community, for our listeners? Dr. Ravin Garg: So Pedro, thanks again for inviting me. You do a great job with these podcasts.  So, I think first and foremost, oncologists right now are under a lot of stress, just in terms of clinical volume. There is concern for research money, and how we get the best care for our patients. So I think this article is very important because it helps bring together, as you had mentioned, the stakeholders throughout academic to community practice and everywhere in between, and try to find how, as a team with different oncologists who partake in different aspects of oncology, can come together to streamline the process to try to get our patients on trials, or certainly have them have availability of trials, just if they are interested in going on them. Being in practice, we have had several challenges that we can talk about throughout this podcast, but I think it is a very important paper because it recognizes that at the end of the day, it takes a team effort for all of us in academics, community, industry, and pharmaceuticals to really come together as a team to really help put forth the trials for our patients. Dr. Pedro Barata: So, from the perspective of a community oncologist, how do you put together, or maybe you can describe some of the challenges that you see to increase trial participation in the community? Dr. Ravin Garg: Yes, Pedro, that is a great question, and it is something that I keep on thinking about and trying to find ways to be better at it myself. But I will say some of the challenges as a community doctor that I have seen for myself and talking to other colleagues. Number one, I do think there is a lot of stress on doctors in the community in general, Pedro. Oftentimes we are tasked to see a wide smorgasbord of patients, so we may not have the luxury of being a specialist in any particular tumor subtype. Like oftentimes, we will have to see lung cancer, the next one will be breast cancer, the next one could be CML, the next one could be thrombocytopenia. And as you know better than I do, Pedro, the field in each one of these disciplines is changing so rapidly: molecular genomics, radioligand treatments, different imaging tests, MRD testing for some of our hematologic malignancies. And I think one challenge we have in community is just keeping up with the basics of Oncology 101. In the process of doing that, it can be very difficult to sometimes remember that we have very exciting trials available for our patients. So, I think a lot of it is the day in and day out of being an oncologist is so taxing at times that oftentimes a research trial is not the first thing in our head space when we see a patient. I think number two, Pedro, at least in the community, and perhaps this is with academics too, is that we are bombarded, I would say, by a lot of messaging these days. We have in-baskets to go through, labs to go through, things of that nature. And in the process of a patient visit, seeing them, doing an exam, taking a history, trying to go over the NCCN guidelines on best practice for how to manage their care, at least for me at times, it is very hard to remember, "Hey, there might be a great trial available, whether within our network or maybe partnering with an academic center." So getting through a day can be fraught with a lot of peril and just difficulties, I would say. And I would say number three, Pedro, at least as, you know, I am in a private practice where I do see a wide range of benign and malignant hematology and solid tumors, so I would not call myself a specialist. And I think the challenge with that, at least for trials, Pedro, is that when you are a specialist or perhaps you are focusing on a couple of disease subtypes, you become more of an authoritative voice in those types of tumors, and you might be more aware of the trials within your network or perhaps in proxy with an academic center that you can offer your patient. So I think when sometimes we spread ourselves too thin, it can be very hard to be a thought leader, if you will, in a particular subtype of a malignancy, let's say, and maybe not be aware of a trial that could be really well-suited for your patient. In terms of ideas that myself and colleagues have had in terms of helping mitigate against some of these, I would say, setbacks or issues in the practice for trial enrollment, some of the things we have talked about, Pedro, is, number one, is we do partner with academic centers. So we live here in Maryland. We have several really fantastic academic centers. So, you know, oftentimes, not just within our practice of Maryland Oncology Hematology, we have a lot of great trials available here too, for certain, but in addition to that, we will often times work with doctors at Georgetown, Johns Hopkins, and Maryland if they have a compelling trial that we do not have within our network. It is really of the patient's interest, Pedro, to reach out to them in a collaborative manner to see if they have a trial that might be really compelling for your patient. So I do find myself collaborating a lot with colleagues in, like talented like yourself in academics. You know, I think you do a lot of GU malignancies. So as an example, like partnering with colleagues who are GU experts and say, "Hey, we have a patient with stage IV renal cell. These are the standard options I know, but are there any trials that you might have available?" I think the other thing that has been very helpful for us is having navigators within research, Pedro. Like as an example, what has really helped the uptake of trial enrollment for our center in Annapolis is having a research navigator because often times what they can do is, a priori, Pedro, before you see the patient and you are kind of formulating a standard of care treatment plan perhaps, they might tug you on the shirt and say, "Hey, we have a great trial here through Sarah Cannon, or there might be something else out there." And being aware of that when you go into a patient's room really provides a nice arena, if you will, to go and say, "The standard of care is here, but hey, we have a trial option that might be well suited for you, maybe perhaps even better, that we can talk about, too." So having research support in the community is really a huge boon, I think, Pedro, for us to really increase our enrollment for patients onto trials. Dr. Pedro Barata: Yes, I really love that, Ravin. So, let me switch gears a bit. I would love for you to talk a little bit about patient advocacy because they do play a huge role in cancer, and they address many barriers. How do you think we should leverage the patient advocacy groups to reduce patient burden and maybe have them really leverage patient advocacies to improve representation in clinical trials? What do we think we can do more? Dr. Ravin Garg: Oh, Pedro, I think they are very critically important. As a clinical oncologist now, and I would say this is for anyone in the field of medicine, you are exactly right. I think patients are bombarded by information. There are a lot of things online, whether it be TikTok, Facebook, Google, Yahoo, and people really just have a lot of information given to them. And some of it is fact driven, and some of it is not, Pedro. And oftentimes, I do think there can be at times a mistrust with some medical personnel. I think we are in an era where we are seeing that to some degree with some attributes of medicine. And I think of it as an opportunity for education for the patient and for myself as a physician. And I think patient advocates, to your point, which was well taken, serve as a bridge to both. And what I mean is that, you know, patient advocates are wonderful. They are, I think, outstanding communicators. They almost are a neutral party, Pedro, where many patients feel that they are an independent source of information that is free of bias, if you will. They are there to provide support, emotional support, scientific support for patients so they can make an informed decision. So, in terms of our practice right now, patient advocates is something that we are evolving in that capacity, I would say, Pedro. I think now more than ever, having more people as bridges of communication with care providers along with patients is of critical importance. And I would venture a guess, and I think this has been published, where patient advocates really can help tremendously in familiarizing patients with trials and what they are all about and maybe clear up some misconceptions of what trials, what the mission of trials are. Because I do think some patients, at least I have had a few over the years, where when they hear the term trial, they almost think they are being experimented upon, when, in point of fact, they could really help advance their care. That messaging along the way for some can may be mixed up a little bit. And so I think patient advocates is a really great way to offer more information for patients with a source they find very independent and trustworthy, if you will. And it can really help expedite, and I think make a more fruitful conversation for care providers, whether academic or community, and they might be more open-minded in terms of enrolling onto a trial. Dr. Pedro Barata: Wonderful. Yes, I agree. I agree with you completely.  So let's focus a little bit now on the folks designing the studies. We usually call them the sponsors. It might be an academic sponsorship, if you will, but we can also have pharma being the sponsor of a study. The angle from an academic design, it is not necessarily the same as what happens when we have pharma. And from that angle, how do you think a more inclusive research can be promoted? Dr. Ravin Garg: Oftentimes with trials, I think keeping them simple, as simple as we can. And what I mean by that is, often times for trials, Pedro, even for care providers who are enrolling, it can be daunting when there are a lot of different things involved, particularly, let's say, for investigator sponsored, which are incredibly brilliant science, incredible, but it can be a little bit daunting for patients and even the referring physician to talk about getting translational specimens, imaging, traveling to certain centers to get scans and biopsies and even different diagnostic testing like PSMA testing for, you know, prostate cancer. And it can, I think, be very intimidating for patients in terms of what might be required of him or her to enter onto a trial. Like, "This is not what I signed up for. This is laborious. This is a full time job for me. Do I have to pay for parking to go to a city? Do I have to pay for these imaging tests? And do I have to stay in a place for my family to enroll onto a trial?" So I think keeping trials as simple as possible, but yet cull the data we need as investigators where we can really advance the care, hopefully get approval for a drug, but also learn more about the medication and how it works for our patients. So I think simplifying language for trial is very important. I know when I have gone over studies for patients, Pedro, if it is a voluminous amount of information, they can right away get very intimidated. "Like, oh my goodness, this is like a term paper for college again," you know? I am joking, but you know, keeping language simplified is very important, I think, number one. And I feel that sometimes when they are asked to do a lot of different diagnostic testing, which is very important for translational work, I 100% understand, but I do think sometimes patients can get a little bit off put, if you will, and frustrated with the whole process of doing it. The second thing for our patients, Pedro, that they have mentioned to us when we put them on trials, not just within our own site but elsewhere, is that it takes a lot of time in terms of collecting information, perhaps a washout period from their last standard of treatment prior to enrollment onto a study. Many patients, Pedro, as you know better than I do, are in maybe crisis in terms of their health and their cancer might be growing, promulgating out of control, and they worry about not being able to expeditiously start onto a treatment, onto a trial. So that can lead to a lot of frustration. And one thing that you brought up, which was outstanding for me, is the enrollment criterion for some of our patients is felt to be somewhat strict. We have had some patients who may have had a remote history of a stage I malignancy that was by all accounts in remission, you know, let's say 4 or 5 years in the past, and the risk of recurrence at this point would be incredibly low, but they may not be able to enter onto a study because of some stringent criterion put forth. And that can be a little bit frustrating. In fact, I have had one or two patients who, as an example, with kidney issues, but the GFR was about 60, like right near a cutoff that oftentimes, as you know, we use where you can get into trial or not. And you know, if they are at 58, as an example, and otherwise they are a picture of health, a great candidate for a trial that will likely advance their care, and if the entry criterion is too stringent, that might be a lost opportunity for all parties involved, all stakeholders, if you will. I do appreciate the criterion for entry onto studies cannot be too liberalized. You have to have a certain baseline, but there is a little bit of a gray area and tension, of sorts, if you will, where the patient has a comorbid illness that is a disqualifying offense, but in practicality, perhaps it shouldn't be, especially if they are motivated and there is an opportunity to really advance their care. We have run into, not often, but sometimes in the past, I should say, where patients have been very off put because we try to get them onto a study and there may have been a particular feature or attribute in their underlying care that they couldn't get onto it. So I think having a little bit more thoughtfulness, perhaps, in terms of entry criterion and practicality, if you will, I think would really help enrollment onto studies. Dr. Pedro Barata: Really well said. Is there anything else that you would like to tell our listeners before we wrap up the podcast today? Dr. Ravin Garg: I would say just macroscopically speaking, it is really an honor to be an oncologist. I think I speak for both of us. Anyone listening who is thinking about the field, it is tremendous. Just the research, the bravery of our patients, and the thoughtfulness of our scientists like Pedro and translationalists and clinical trialists is really awe inspiring. So I have really loved this field. I will say from a trial perspective, we really need to enter as many patients as we can onto trials because the science is so brilliant now, the genomic underpinnings of the tumor, we are making great strides as a team of clinicians and scientists, translationalists. So the more that we can get people onto trials and get approved drugs, it is going to help them out in the end. So I think it is such an important time for all of us to come together as a community, find the best way to help our patients out. And clinical trials have to be at the forefront of how we can continue to advance care for our patients. Dr. Pedro Barata: Yeah, no Ravin, I really agree with you. We really need to increase access to clinical studies, and actually your paper is a great step in that direction by raising awareness, bringing up solutions, and again, collaboration, collaboration, collaboration is really a multidisciplinary effort to accomplish that.  Thank you so much for sharing your fantastic thoughts and insights with us. Dr. Ravin Garg: Thank you, Pedro. I am- you do a wonderful job with these podcasts. I am really honored to meet you and to be part of this. Dr. Pedro Barata: And thank you to our listeners for your time today. I encourage you to check out Dr. Garg's article in the 2025 ASCO Educational Book. We will post a link to the paper in our show notes. And please join us again next month on By the Book for more insights on key advances and innovations that are shaping modern oncology. Thank you for your attention. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow today's speakers:          Dr. Pedro Barata   @PBarataMD    Dr. Ravin Garg Follow ASCO on social media:          @ASCO on X      ASCO on Bluesky     ASCO on Facebook       ASCO on LinkedIn       Disclosures:       Dr. Pedro Barata:   Stock and Other Ownership Interests: Luminate Medical   Honoraria: UroToday   Consulting or Advisory Role: Bayer, BMS, Pfizer, EMD Serono, Eisai, Caris Life Sciences, AstraZeneca, Exelixis, AVEO, Merck, Ipson, Astellas Medivation, Novartis, Dendreon   Speakers' Bureau: AstraZeneca, Merck, Caris Life Sciences, Bayer, Pfizer/Astellas   Research Funding (Inst.): Exelixis, Blue Earth, AVEO, Pfizer, Merck    Dr. Ravin Garg: Patents, Royalties, Other Intellectual Property: Creator, editor, and writer of hemeoncquestions.com  

 Alissa Bayer graduated with her MBA from McCombs in 2004 and quickly launched Milk and Honey Spa. After over 20 years in business and 10 locations nationwide, in this episode she reflects back on the lessons she learned at McCombs, what it's been like to navigate changing social norms and how she hopes her business sparks joy in the wider community.

This episode covers: Cardiology This Week: A concise summary of recent studies DAPT: how short is too short Obesity and atrial fibrillation Milestones: COURAGE  Host: Emer Joyce Guests: Carlos Aguiar, Steffen Massberg, Prash Sanders Want to watch that episode? Go to: https://esc365.escardio.org/event/2178 Want to watch that extended interview on dual antiplatelet therapy (DAPT) and shortening its optimal duration, go to: https://esc365.escardio.org/event/2178?resource=interview   Disclaimer  ESC TV Today is supported by Bristol Myers Squibb and Novartis through an independent funding. The programme has not been influenced in any way by its funding partners. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. The ESC is not liable for any translated content of this video. The English language always prevails.   Declarations of interests Stephan Achenbach, Yasmina Bououdina, Emer Joyce, Nicolle Kraenkel and Steffen Massberg have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Prashanthan Sanders has declared to have potential conflicts of interest to report: advisory board representative University of Adelaide, Medtronic, Boston Scientific, CathRx, Abbott and Pacemate as well as research grants for University of Adelaide: Medtronic, Abbott, Boston Scientific, Becton Dickson. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Der von Felix auserkorene Weihnachtsmonat Dezember ist da – und unserem madrilenischen Exil-Meck-Pommer kommt's jetzt schon zu den Ohren raus. Doch was vernehmen wir da aus Madrid? Der Herr findet Spaß am Elf on the Shelf und legt beim Wichtelbasteln sogar selbst Hand an? Vielleicht geschehen also nicht nur in Whoville Weihnachtswunder, sondern auch bei unserem höchsteigenen Grinch. Oder heißt der in Spanien Gringo? Spanien ist vermutlich – auch nach dem Weggang von Xabi Alonso von Bayer – weiterhin ein gutes Stichwort für unsere heutige Spielanalyse: Ballspielverein 09 aus Dortmund gegen die Leverkusener Werkself(en). Sind doch mit Aleix García und Alejandro Grimaldo mindestens zwei der wichtigsten Leverkusener Akteure iberischer Natur am Werk. Naturgemäß auf den Punkt und messerscharf wird das Pokalspiel also weganalysiert, und die häufig provokante Frage, ob es denn ein unverdienter Sieg gewesen sei, mit einem „Ja, aber …“ beantwortet. Anschließend reden wir noch mit Hörer Yannik über die Last der späten Einwechslung – und darüber, was Kroos und Kroos eigentlich so in der Halbzeit eines herkömmlichen Spiels getrieben haben. Spoiler: nicht so wahnsinnig viel. Viel Spaß mit der neuen Folge! Du möchtest mehr über unsere Werbepartner erfahren? [**Hier findest du alle Infos & Rabatte!**](https://linktr.ee/luppentv) Für Werbe- und Partnerschaftsanfragen im Podcast EINFACH MAL LUPPEN meldet euch hier: werbung@studio-bummens.de

Audio roundup of selected biopharma industry content from Scrip over the business week ended November 28, 2025. In this episode: 2027 Medicare price cuts likely not as large as CMS estimates; Zai Lab leads DLL3 lung cancer ADC race; Phase II failure for J&J's Alzheimer's asset posdinemab; Bayer's positive Phase III data for asundexian in stroke; and Pfizer/Astellas's Padcev's first big win in bladder cancer study. Story links: https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-R4RCDF2RXVGVHPEX2WQ7A3JVKU/ This episode was produced with the help of AI text-to-voice and voice emulation tools. Playlist: soundcloud.com/citelinesounds/sets/scrips-five-must-know-things

Today, we'll be tackling the future of prostate cancer care. We'll be reflecting on what prostate cancer care means in practice, how the way we think about the disease is shifting, and must continue to shift in the years ahead. Scientific advances have transformed treatment in recent years, yet the lived reality of prostate cancer still extends far beyond the clinic. The disease reshapes daily life, and may leave men and their families grappling with difficult choices about how best to manage it.  Dr. Güneş Taylor is joined by three key voices at the centre of this story, following the prostate cancer journey from diagnosis through to long-term management, and asking how patients and clinicians can work together to re-think what patient-centred care could mean in the years to come. This episode is brought to you in collaboration with Bayer, part of their Prostate Cancer Perspectives series.  PP-UN-ONC-GB-0168. November 2025 References Bray F, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229-263 (Prostate cancer is the second most common cancer in men and the fifth leading cause of cancer death worldwide) James D, et al. The Lancet Commission on prostate cancer: planning for the surge in cases. Lancet. 2024;403(10437):1683–1722 (Each year, around 1.5 million men are diagnosed and nearly 400,000 lose their lives to the disease.1 And the numbers are rising. Diagnoses are projected to double from 1.4 million annually in 2020 to 2.9 million by 2040) Siegel RL, et al. Cancer statistics, 2022. Ca Cancer J Clin. 2022;72:7–33 (In the U.S., the proportion of men diagnosed with advanced-stage prostate cancer has doubled in recent years, due to increasing incidence of advanced-stage disease and changing guidelines regarding the prostate specific antigen screening test, implemented in the U.S. in 2012) Dodkins J, et al. Geographic, socioeconomic and demographic inequalities in the incidence of metastatic prostate cancer at time of diagnosis in England: a population based evaluation. BMJ Oncology. 2025;4:e000643 (In England, nearly one in five men only receive a diagnosis once their cancer has spread) Calvo-Schimmel A, et al. Supportive care interventions and quality of life in advanced disease prostate cancer survivors: An integrative review of the literature. Can Oncol Nurs J. 2021;31(4):412-429 (Advanced prostate cancer is often associated with long-term challenges leading to greater levels of unmet needs in supportive care) Learn more about your ad choices. Visit podcastchoices.com/adchoices

Are multivitamins bad for you? How could that be? In this video, I'll share the truth about the multivitamin scam. Find out about the vitamins you should never take, supplements that don't work, and the harmful ingredients in your supplements. 0:00 Introduction: Multivitamins truth0:19 Harmful ingredients in supplements 1:45 Synthetic vs. natural vitamins 3:38 Do multivitamins really work?9:32 Natural vitamins and minerals11:17 Fake vitamins exposed! Many multivitamins are made with the cheapest, synthetic ingredients which could be doing more harm than good.The first ingredient in many multivitamins is often calcium carbonate, which is limestone! The first ingredient usually makes up the majority of the product. Magnesium oxide, another common ingredient, is very cheap and has the lowest absorption rate compared to other forms of magnesium. The term “natural” isn't regulated, so ingredients derived from sources such as petroleum and coal tar can be labeled as natural. In nature, vitamins don't exist alone; they are combined with other nutrients and cofactors, which are often missing when you take synthetic vitamins. Biochemistry can not work without cofactors. Although there are nutrients that are difficult to obtain in sufficient amounts from food, that doesn't mean they should be replaced with synthetic multivitamins.Maltodextrin is commonly used as a filler in vitamins and minerals. It's a highly refined industrial starch, classified as a complex carbohydrate, and spikes blood sugar more than sugar. Ascorbic acid is a synthetic part of the vitamin C complex. Approximately 90% is made in China from GMO corn and sulfuric acid. Many people have a genetic issue converting cyanocobalamin, a synthetic form of B12, and folic acid, a synthetic form of B9, into their active forms. This can cause negative side effects in 40% of the population.Almost all of the popular multivitamins are owned by Big Pharma, Big Food, Big Chemical, or large investment groups. For example, Centrum Silver is owned by Pfizer, and One a Day is owned by Bayer. Nature Made is owned by the same company that sells Abilify!Dr. Eric Berg DC Bio:Dr. Berg, age 60, is a chiropractor who specializes in Healthy Ketosis & Intermittent Fasting. He is the Director of Dr. Berg Nutritionals and author of the best-selling book The Healthy Keto Plan. He no longer practices, but focuses on health education through social media.Disclaimer: Dr. Eric Berg received his Doctor of Chiropractic degree from Palmer College of Chiropractic in 1988. His use of “doctor” or “Dr.” in relation to himself solely refers to that degree. Dr. Berg is a licensed chiropractor in Virginia, California, and Louisiana, but he no longer practices chiropractic in any state and does not see patients, so he can focus on educating people as a full-time activity, yet he maintains an active license. This video is for general informational purposes only. It should not be used to self-diagnose, and it is not a substitute for a medical exam, cure, treatment, diagnosis, prescription, or recommendation. It does not create a doctor-patient relationship between Dr. Berg and you. You should not make any change in your health regimen or diet before first consulting a physician and obtaining a medical exam, diagnosis, and recommendation. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition.

In this episode, Kelly, known as Glyphosate Girl on Instagram, shares her profound experience and knowledge about glyphosate. The conversation begins with Kelly's personal narrative on facing multiple health issues, leading her to explore the adverse effects of glyphosate. The discussion encompasses the origins, widespread use, and dangerous impacts of glyphosate on human health and the environment. Furthermore, Kelly sheds light on Monsanto's controversial practices and the ongoing legal battles. She emphasizes the importance of regenerative agriculture as a solution to move away from reliance on such chemicals.     03:04 Introduction to Glyphosate 03:52 Personal Health Journey 07:05 Discovering Glyphosate's Impact 09:32 History and Use of Glyphosate 14:43 Glyphosate in Our Environment 24:24 Health Implications of Glyphosate 27:20 Legal Battles and Public Awareness 28:16 The EPA's Initial Findings on Glyphosate 29:28 Monsanto's Response and Manipulation 30:31 International Agency for Research on Cancer's Findings 32:05 EPA's Controversial Decision 32:43 Political and Regulatory Challenges 38:04 The Role of Regenerative Agriculture 41:56 Bayer's Acquisition and Legal Battles 43:26 Liability Shields and Legislative Efforts 44:55 Public Awareness and Personal Responsibility 51:38 The European Perspective on Glyphosate